|
gptkbp:instanceOf
|
gptkb:stimulant
gptkb:chemical_compound
|
|
gptkbp:ATCCode
|
gptkb:N06BA01
|
|
gptkbp:CASNumber
|
300-62-9
|
|
gptkbp:chemicalFormula
|
C9H13N
|
|
gptkbp:chirality
|
S-enantiomer
|
|
gptkbp:component
|
gptkb:Adderall
gptkb:Benzedrine
gptkb:Evekeo
|
|
gptkbp:discoveredBy
|
gptkb:Lazăr_Edeleanu
|
|
gptkbp:discoveredIn
|
1887
|
|
gptkbp:eliminationHalfLife
|
11-14 hours
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:hasEnantiomer
|
gptkb:dextroamphetamine
|
|
gptkbp:hasInChIKey
|
KWTSXDURSIMDCE-SECBINFHSA-N
|
|
gptkbp:hasSMILES
|
CC(CC1=CC=CC=C1)N
|
|
gptkbp:hasUNII
|
TZ47U0516Y
|
|
gptkbp:isomerOf
|
gptkb:amphetamine
|
|
gptkbp:IUPACName
|
(S)-1-phenylpropan-2-amine
|
|
gptkbp:legalStatus
|
Schedule II controlled substance (US)
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
135.21 g/mol
|
|
gptkbp:PubChem_CID
|
DB00182
5362440
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
anxiety
increased heart rate
insomnia
|
|
gptkbp:usedFor
|
treatment of ADHD
treatment of narcolepsy
|
|
gptkbp:bfsParent
|
gptkb:Amphetamine
|
|
gptkbp:bfsLayer
|
7
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
levoamphetamine
|